Lipid profile alterations and biomarker identification in type 1 diabetes mellitus patients under glycemic control
Authors:
Open Access
- 12 August 2024
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 24 (1) , 1-11
Abstract
Type 1 diabetes mellitus (T1DM) is well-known to trigger a disruption of lipid metabolism. This study aimed to compare lipid profile changes in T1DM patients after achieving glucose control and explore the underlying mechanisms. In addition, we seek to identify novel lipid biomarkers associated with T1DM under conditions of glycemic control. A total of 27 adults with T1DM (age: 34.3 ± 11.2 yrs) who had maintained glucose control for over a year, and 24 healthy controls (age: 35.1 + 5.56 yrs) were recruited. Clinical characteristics of all participants were analyzed and plasma samples were collected for untargeted lipidomic analysis using mass spectrometry. We identified 594 lipid species from 13 major classes. Differential analysis of plasma lipid profiles revealed a general decline in lipid levels in T1DM patients with controlled glycemic levels, including a notable decrease in triglycerides (TAGs) and diglycerides (DAGs). Moreover, these T1DM patients exhibited lower levels of six phosphatidylcholines (PCs) and three phosphatidylethanolamines (PEs). Random forest analysis determined DAG(14:0/20:0) and PC(18:0/20:3) to be the most prominent plasma markers of T1DM under glycemic control (AUC = 0.966). The levels of all metabolites from the 13 lipid classes were changed in T1DM patients under glycemic control, with TAGs, DAGs, PCs, PEs, and FFAs demonstrating the most significant decrease. This research identified DAG(14:0/20:0) and PC(18:0/20:3) as effective plasma biomarkers in T1DM patients with controled glycemic levels.Keywords
Funding Information
- Training Project for Leading Talents of the Health and Family Planning Commission of Yunnan Province (L-201624)
- Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases open project (DKME202218)
- Yunnan Clinical Medical Research Center open project (N2020LCZXKF-NM06)
- Special Project for “Famous Doctor” of Yunnan Ten Thousand Talents Plan (YNWR-MY-2019-020)
This publication has 53 references indexed in Scilit:
- Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetesJournal of Endocrinological Investigation, 2024
- Circulating metabolomic and lipidomic changes in subjects with new-onset type 1 diabetes after optimization of glycemic controlDiabetes Research and Clinical Practice, 2023
- Lipidomic profiling of plasma free fatty acids in type-1 diabetes highlights specific changes in lipid metabolismBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2021
- Lipidomic Abnormalities During the Pathogenesis of Type 1 Diabetes: a Quantitative ReviewCurrent Diabetes Reports, 2020
- Absolute quantitative lipidomics reveals lipidome-wide alterations in aging brainMetabolomics, 2017
- Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetesDiabetologia, 2017
- Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and HumansCell Reports, 2017
- Hyperglycemia and duration of diabetes as risk factors for abnormal lipids: a cross sectional survey of 19,757 patients with type 2 diabetes in ChinaJournal of Endocrinological Investigation, 2014
- Lipid disorders in type 1 diabetesDiabetes & Metabolism, 2009
- High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithmBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2004